High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort

Claudia Ott, Anne Liebold, Angela Takses, Ulrike G Strauch, Florian Obermeier, Claudia Ott, Anne Liebold, Angela Takses, Ulrike G Strauch, Florian Obermeier

Abstract

Background. Iron-deficiency anemia is described to be a common problem in patients with inflammatory bowel disease (IBD), which is frequently associated with a reduced quality of life. Therefore, the aim of this study is to assess the prevalence of iron deficiency anemia in a population-based cohort at time of first diagnosis and during the early course of the disease. Methods. As far as available, lab values of patients registered in the population-based "Oberpfalz cohort" were screened. In anemic patients, we further investigated all laboratory results to differentiate between iron deficiency and other reasons for anemia. All patients with any kind of anemia were interviewed separately according to symptoms of iron-deficiency anemia and administration of iron. Results. In total, we evaluated hemoglobin values of 279 patients (183 Crohn's disease, 90 ulcerative colitis, and 6 indeterminate colitis). Lab data which allowed further differentiation of the type of anemia were available in 70% of anemic patients, in 34.4% values of iron, ferritin and transferrin saturation had been measured. At time of first diagnosis, an iron-deficiency anemia was diagnosed in 26 of 68 patients with anemia (38.2%, 20 CD, 4 UC, and 2 IC patients), but only 9 patients (34.6%) received subsequent iron therapy. After one year, 27 patients were identified to have an iron-deficiency anemia (19 CD, 8 UC), 20 of them were treated with iron (71.4%). Of 9 patients with proven iron-deficiency anemia at time of first diagnosis and subsequent administration of iron, 5 (55.5%) had iron-deficiency anemia despite permanent treatment after one year. In total, 38 patients (54.3%) did not receive any iron substitution at all despite of proven iron-deficiency anemia, and only 13 patients of 74 patients were treated with intravenous iron (17.6%). Conclusion. We found a high prevalence of iron-deficiency anemia at different points during the early course of disease in this population-based cohort of IBD patients. Surprisingly, only in one-third of patients with proven anemia, further diagnostic approach was undertaken. Even patients with diagnosed iron-deficiency anemia were infrequently and inconsequently treated with iron preparations, despite the high impact on quality of life.

Figures

Figure 1
Figure 1
Hb-levels at first diagnosis.
Figure 2
Figure 2
Characteristics of all patients with anemia during the different observation points.
Figure 3
Figure 3
Duration of iron supplementation.
Figure 4
Figure 4
Digestibility of oral iron preparations.

References

    1. Podolsky DK. Inflammatory bowel disease. The New England Journal of Medicine. 2002;347(6):417–429.
    1. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases. 2006;12(2):123–130.
    1. Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2006;12(1):47–52.
    1. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190–1197.
    1. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflammatory Bowel Diseases. 2003;9(5):316–320.
    1. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment. Haematologica. 2010;95(2):199–205.
    1. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Alimentary Pharmacology and Therapeutics. 2006;24(11-12):1507–1523.
    1. Ott C, Obermeier F, Thieler S, et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. European Journal of Gastroenterology and Hepatology. 2008;20(9):917–923.
    1. Giannini S, Martes C. Anemia in inflammatory bowel disease. Minerva Gastroenterologica e Dietologica. 2006;52(3):275–291.
    1. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. American Journal of Medicine. 2004;116(supplement 7):44S–49S.
    1. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World Journal of Gastroenterology. 2009;15(37):4659–4665.
    1. Weiss G, Goodnough LT. Anemia of chronic disease. The New England Journal of Medicine. 2005;352(10):1011–1023.
    1. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2007;13(12):1545–1553.
    1. Gasche C, Evstatiev R, Haas T, et al. Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseasesconsensus of the Austrian IBD Working Party. Zeitschrift fur Gastroenterologie. 2011;49(5):627–632.
    1. Voegtlin M, Vavricka SR, Schoepfer AM, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. Journal of Crohn’s and Colitis. 2010;4(6):642–648.
    1. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflammatory Bowel Diseases. 2009;15(10):1485–1491.
    1. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. European Journal of Gastroenterology & Hepatology. 2011;23(11):1029–1035.
    1. Schröder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology. 2005;100(11):2503–2509.
    1. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. The Lancet. 2007;369(9572):1502–1504.
    1. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology. 2008;103(5):1182–1192.
    1. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scandinavian Journal of Gastroenterology. 2009;44(7):838–845.
    1. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of during treatment with recombinant human erythropoietin. Cancer. 1994;73(10):2535–2542.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner